US Edition
EpiEndo publishes new data supporting glasmacinal’s potential in COPD - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
EpiEndo publishes new data supporting glasmacinal’s potential in COPD - Pharmafile
EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of its lead asset, EP395 (glasmacinal), as an oral treatment for chronic obstructive pulmonary disease (COPD). The published data includes findings from both clinical and preclinical studies. A clinical study conducted in collaboration with the Fraunhofer […] The post EpiEndo pub…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium